These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35559349)

  • 1. Biomarkers in Medicines Development-From Discovery to Regulatory Qualification and Beyond.
    Hendrikse NM; Llinares Garcia J; Vetter T; Humphreys AJ; Ehmann F
    Front Med (Lausanne); 2022; 9():878942. PubMed ID: 35559349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020.
    Bakker E; Hendrikse NM; Ehmann F; van der Meer DS; Llinares Garcia J; Vetter T; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2022 Jul; 112(1):69-80. PubMed ID: 35137949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
    Isaac M; Vamvakas S; Abadie E; Jonsson B; Gispen C; Pani L
    Eur Neuropsychopharmacol; 2011 Nov; 21(11):781-8. PubMed ID: 21903360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment.
    Walker EG; Brumfield M; Compton C; Woosley R
    Ther Innov Regul Sci; 2014 Mar; 48(2):236-245. PubMed ID: 30227514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers as drug development tools: discovery, validation, qualification and use.
    Kraus VB
    Nat Rev Rheumatol; 2018 Jun; 14(6):354-362. PubMed ID: 29760435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Medicines Agency experience with biomarker qualification.
    Manolis E; Koch A; Deforce D; Vamvakas S
    Methods Mol Biol; 2015; 1243():255-72. PubMed ID: 25384751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical biomarker qualification.
    Sauer JM; Porter AC;
    Exp Biol Med (Maywood); 2018 Feb; 243(3):222-227. PubMed ID: 29171289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNS biomarkers: Potential from a regulatory perspective: Case study - Focus in low hippocampus volume as a biomarker measured by MRI.
    Isaac M; Gispen-de Wied C
    Eur Neuropsychopharmacol; 2015 Jul; 25(7):1003-9. PubMed ID: 25957799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building a roadmap to biomarker qualification: challenges and opportunities.
    Amur SG; Sanyal S; Chakravarty AG; Noone MH; Kaiser J; McCune S; Buckman-Garner SY
    Biomark Med; 2015; 9(11):1095-105. PubMed ID: 26526897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enabling technologies driving drug research and development.
    Vass P; Akdag DS; Broholm GE; Kjaer J; Humphreys AJ; Ehmann F
    Front Med (Lausanne); 2023; 10():1122405. PubMed ID: 36968842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
    Rasmussen DGK; Anstee QM; Torstenson R; Golding B; Patterson SD; Brass C; Thakker P; Harrison S; Billin AN; Schuppan D; Dufour JF; Andersson A; Wigley I; Shumbayawonda E; Dennis A; Schoelch C; Ratziu V; Yunis C; Bossuyt P; Karsdal MA
    J Hepatol; 2023 Apr; 78(4):852-865. PubMed ID: 36526000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pathway for qualification of novel methodologies in the European Medicines Agency.
    Manolis E; Vamvakas S; Isaac M
    Proteomics Clin Appl; 2011 Jun; 5(5-6):248-55. PubMed ID: 21538915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting Adoption of the 3Rs through Regulatory Qualification.
    Walker EG; Baker AF; Sauer JM
    ILAR J; 2016 Dec; 57(2):221-225. PubMed ID: 28053074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Alzheimer's Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation.
    Cummings J; Kinney J
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888671
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.
    Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S
    J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective.
    Viceconti M; Tome M; Dartee W; Knezevic I; Hernandez Penna S; Mazzà C; Caulfield B; Garcia-Aymerich J; Becker C; Maetzler W; Troosters T; Sharrack B; Davico G; Corriol-Rohou S; Rochester L;
    Front Med (Lausanne); 2022; 9():996903. PubMed ID: 36213641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.
    Dieterle F; Sistare F; Goodsaid F; Papaluca M; Ozer JS; Webb CP; Baer W; Senagore A; Schipper MJ; Vonderscher J; Sultana S; Gerhold DL; Phillips JA; Maurer G; Carl K; Laurie D; Harpur E; Sonee M; Ennulat D; Holder D; Andrews-Cleavenger D; Gu YZ; Thompson KL; Goering PL; Vidal JM; Abadie E; Maciulaitis R; Jacobson-Kram D; Defelice AF; Hausner EA; Blank M; Thompson A; Harlow P; Throckmorton D; Xiao S; Xu N; Taylor W; Vamvakas S; Flamion B; Lima BS; Kasper P; Pasanen M; Prasad K; Troth S; Bounous D; Robinson-Gravatt D; Betton G; Davis MA; Akunda J; McDuffie JE; Suter L; Obert L; Guffroy M; Pinches M; Jayadev S; Blomme EA; Beushausen SA; Barlow VG; Collins N; Waring J; Honor D; Snook S; Lee J; Rossi P; Walker E; Mattes W
    Nat Biotechnol; 2010 May; 28(5):455-62. PubMed ID: 20458315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes.
    Viceconti M; Hernandez Penna S; Dartee W; Mazzà C; Caulfield B; Becker C; Maetzler W; Garcia-Aymerich J; Davico G; Rochester L
    Sensors (Basel); 2020 Oct; 20(20):. PubMed ID: 33092143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.
    Hill DLG; Schwarz AJ; Isaac M; Pani L; Vamvakas S; Hemmings R; Carrillo MC; Yu P; Sun J; Beckett L; Boccardi M; Brewer J; Brumfield M; Cantillon M; Cole PE; Fox N; Frisoni GB; Jack C; Kelleher T; Luo F; Novak G; Maguire P; Meibach R; Patterson P; Bain L; Sampaio C; Raunig D; Soares H; Suhy J; Wang H; Wolz R; Stephenson D
    Alzheimers Dement; 2014 Jul; 10(4):421-429.e3. PubMed ID: 24985687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.